Compare HLI & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLI | BIO |
|---|---|---|
| Founded | 1972 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 8.2B |
| IPO Year | 2015 | N/A |
| Metric | HLI | BIO |
|---|---|---|
| Price | $184.42 | $325.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $203.63 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 425.5K | 154.0K |
| Earning Date | 01-27-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 26.59 | N/A |
| EPS | ★ 6.19 | N/A |
| Revenue | ★ $2,565,361,000.00 | $2,557,500,000.00 |
| Revenue This Year | $15.19 | $1.62 |
| Revenue Next Year | $13.05 | $2.26 |
| P/E Ratio | $29.51 | ★ N/A |
| Revenue Growth | ★ 21.00 | N/A |
| 52 Week Low | $137.99 | $211.43 |
| 52 Week High | $211.78 | $373.69 |
| Indicator | HLI | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 65.53 |
| Support Level | $173.68 | $300.26 |
| Resistance Level | $185.84 | $305.62 |
| Average True Range (ATR) | 3.52 | 7.60 |
| MACD | 0.85 | 2.31 |
| Stochastic Oscillator | 88.32 | 92.18 |
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.